Place of topical corticosteroids in therapy of allergic rhinitis
https://doi.org/10.21518/2079-701X-2018-8-72-76
Abstract
Treatment of allergic rhinitis (AR) is an important medical and social problem. Priority in choosing the tactics of managing patients with this pathology is the appointment of intranasal corticosteroids in the form of basic AR therapy and as part of combined schemes.
About the Authors
S. V. Ryazantsev
Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
S. A. Artuyshkin
I.I. Mechnikov North-Western Medical University of the Ministry of Health of Russia, Saint-Petersburg
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
M. A. Budkovaya
Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of Russia
Russian Federation
Russian Federation
E. S. Artemyeva
Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. ARIA. Allergic rhinitis and its impact on bronchial asthma. Allergologiya, 2001, 3 (app.): 43-56.
2. Drobik OS. Allergic rhinitis: modern approaches to diagnosis and therapy. Effective pharmaco-therapy. Pulmonologiya i Otorinolaringologiya, 2014, 2 (29): 54-58.
3. Kudaibergenova SF . Informative value of the cytological method in allergic rhinitis with concomitant pathology of ENT-organs. Vestnik Otorinolaringologii, 2010, 3: 37.
4. Gurov AV. Modern possibilities of diagnostics and treatment of allergic rhinitis. RMJ, 2008, 16 (2): 103-105.
5. Turovsky AB. Allergic rhinitis: a new solution to the old problem. Meditsinsky Sovet, 2016, 6: 44-50.
6. Ovchinnikov AYu, Nosulya EV, Ryazantsev SV. Allergic rhinitis: a new solution to the old problem. Materials of the 19th Congress of Otorhinolaryngologists. Effektivnaya Farmakoterapiya. Pulmonologiya i Otorinolaringologiya, 2016, 1 (20): 38-44.
7. Nesterova KI, Nesterova AA. The niche of topical antihistamines in s easonal allergic rhinitis. Dnevnik Kazanskoy Meditsinskoy Shkoly, 2008, 1 (7): 88-92.
8. Svistushkin VM, Morozova SV, Zolotova AV. New features of etiopathogenetic therapy of allergic rhinitis. Meditsinsky Sovet, 2017, 8: 68-71.
9. Rossi O et al. Escaping the trap of allergic rhinitis. Clin Mol Allergy, 2015, 13(1): 17. doi: 10.1186/s12948-015-0023.
10. Bousquet J et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy, 2008, 63(Suppl 86): 8-160.
11. Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. Asthma Allergy, 2016, 9: 135-143. doi:
12. 2147/JAA.S98172.
13. Mahatme MS et al. Comparison of efficacy, safety, and cost-effectiveness of montelukastlevocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Pharmacol. 2016, 48(6): 649-653. doi: 10.4103/0253-7613.194854.
14. Fedoskova TG, Nosulya EV, Nenasheva NM. Advance in the treatment of allergic rhinitis. Effektivnaya Farmakoterapiya. Allergologiya i Immunologiya, 2017, 28: 14-20.
15. Bogova AV, Ilyina NI, Luss LV. Trends in studies of allergic disease epidemiology in Russia over the past 10 years. Ros. allergol. zhurnal, 2008, 6: 3-14.
16. Kurbacheva OM, Ilina NI, Lousse L.V. Allergic rhinitis: analysis of the quality of diagnosis, rationality and reasonableness of choice of therapy. Allergologiya, 2003, 3: 51-54.
17. Karpova EP, Tulupov DA. The role of the nasal spray mometasone furoate in the treatment of chronic nasopharyngeal pathology in children. Effektivnaya Farmakoterapiya. Pediatriya, 2012, 1: 16-17.
18. Ovchinnikov AYu, Edzhe MA, Khon EM. How to optimize management of patients with allergic rhinitis. RMJ. Otorhinolaryngologiya, 2016, 4: 221-225
19. Ryazantsev SV. Barrier therapy: a new direction in the treatment of allergic rhinitis. Ros. Otorinolar. 2014, 2: 148-153.
20. Gushchin IS, Kurbacheva OM. Allergy and allergen-specific immunotherapy. M.: Pharmarus Print Media. 2010. 228 pp
21. Maltseva GS, Budkova MA. Substantiation of pathogenetic aspects and clinical administration of topical decongestants. Consilium Medicum, 2016, 18 (11): 49-54.
22. Lopatin AS, Sidorenko IV, Zakharzhevskaya TV, Krallina IP, Kosyakova EI. Efficacy of nasonex in the treatment of allergic rhinitis and chronic polyposis rhinosinusitis. Vestnik Otorinolar, 2000, 4: 60-63
23. Kryukov AI, Kunelskaya NL, Tsarapkin GYu, Tovmasyan AS, Panasov SA. Intranasal gluco-corticosteroids: the drugs of choice for the treatment of inflammatory pathology of the nasal cavity and paranasal sinuses. RMJ. Otorinolaringologiya, 2016, 21: 1403-1406.
24. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. Investig. Allergol. Clin. Immunol., 2012, 22(1): 1–12.
Review
For citations:
Ryazantsev SV, Artuyshkin SA, Budkovaya MA, Artemyeva ES. Place of topical corticosteroids in therapy of allergic rhinitis. Meditsinskiy sovet = Medical Council. 2018;(8):72-76. (In Russ.) https://doi.org/10.21518/2079-701X-2018-8-72-76
Views:
851
Email this article 